49 Spam-Free Article(s) Found
Article Searches
Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks? https://www.fool.com/investing/2020/04/01/do-clinical-trial-delays-mean-trouble-for-pharmace.aspx?source=iedfolrf0000001 Apr 01, 2020 - Postponed clinical trials might mean a longer time-to-market for certain drugs.
Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus http://www.zacks.com/stock/news/847731/buy-this-high-yield-large-cap-pharma-stock-for-income-amid-coronavirus?cid=CS-ZC-FT-video_blog-847731 Mar 31, 2020 - AbbVie (ABBV) stock popped on Tuesday. This is part of the global pharmaceutical giant's larger 20% surge in the last week as the market tries to mount a comeback amid the coronavirus uncertainty...
Eli Lilly Licenses Immunology Drugs for Up to $880 Million https://www.fool.com/investing/2020/03/31/eli-lilly-licenses-immunology-drugs-for-up-to-880.aspx?source=iedfolrf0000001 Mar 31, 2020 - The pharma giant will develop and market up to four drugs from the pipeline of privately-held Sitryx.
Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children http://www.zacks.com/stock/news/847430/lillys-taltz-gets-fda-nod-for-plaque-psoriasis-in-children?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-847430 Mar 31, 2020 - The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up.
AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic http://www.zacks.com/stock/news/845462/aveo-stops-aml-study-on-ficlatuzumab-amid-coronavirus-pandemic?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-845462 Mar 30, 2020 - AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.
Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia http://www.zacks.com/stock/news/838749/bristol-myers-bmy-clinches-fda-nod-for-ms-drug-zeposia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-838749 Mar 27, 2020 - The FDA approves Bristol Myers' (BMY) Zeposia for the treatment of adults with relapsing forms of multiple sclerosis.
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants http://www.zacks.com/stock/news/834155/pfizers-eczema-drug-eucrisa-gets-fda-approval-for-infants?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-834155 Mar 25, 2020 - Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema.
3 Reasons Pharma Stocks Are a Buy Right Now https://www.fool.com/investing/2020/03/25/3-reasons-pharma-stocks-are-a-buy-right-now.aspx?source=iedfolrf0000001 Mar 25, 2020 - The coronavirus outbreak has made shares of top drugmakers more attractive than they've been in a quite a while.
Agios' IND for PKR Activator AG-946 Gets FDA Clearance http://www.zacks.com/stock/news/832392/agios-ind-for-pkr-activator-ag-946-gets-fda-clearance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-832392 Mar 24, 2020 - The FDA passes Agios' (AGIO) investigational new drug application for its next-generation PKR activator, AG-946. The company plans to begin a phase I study on the same in mid-2020.

Pages: 12345

<<<Page 5